Na+ ion channels
These channels are transmembrane proteins that allow a small amount of Na+ to flow into cells along its electrochemical gradient. In vivo, Na+ channels can be divided into voltage-gated Na+ channels (VGSCs) and epithelial Na+ channels (ENaCs). VGSCs are transmembrane proteins present in different cell types throughout the body. These channels consist of voltage-related activation and time-related inactivation gates that work together to ensure that cells are depolarized within a controllable degree (17). VGSCs act on a specific intracellular domain and interact with various membranes, extracellular matrices (ECM) and cytoskeletal proteins to exert their function (17,18). ENaCs are heteromeric proteins, composed of α, β and γ subunits, that are mainly distributed in the epithelial cells of the far renal units and lung epithelial cells and are highly selective under suitable conditions. These channels serve a key role in organism growth and development, metabolism and energy conversion (19). Since the α and β subunits of VGSC are highly expressed only in cardiomyocytes, skeletal myocytes, neurons and some unexcitable cells. Current research has not demonstrated the function of the VGSC in the kidney, meaning the mechanisms underlying their function bears little significance on the development of proteinuria (20). Therefore, the current review article focused on the role of ENaCs in proteinuria.
ENaCs. ENaCs are non-voltage-dependent channels and have minor impact on potential changes across the cell membrane but with higher selectivity for Na+ over K+ compared with other Na+ channels. ENaCs are highly expressed in the distal renal tubules, the large intestinal epithelium, the exocrine glandular duct, the airway epithelium and the bladder epithelium and can be blocked by amiloride, a pharmaceutical inhibitor and its analogues. Na+ crosses the polarized cell membrane along its electrochemical gradient through ENaCs, while Na+ is pumped out of the cell by the Na+/K+-ATPase, thus maintaining water and Na+ balance and blood pressure (Fig. 1) (21-23). Svenningsen et al (24) demonstrated that impaired glomerular filtration barrier can activate ENaCs. This modulation is affected by several regulatory factors such as proteases. Under physiological conditions, the activity of soluble protease is notably low in urine (25). However, this rises in proteinuria, which is also characterized by increased levels of plasma proteinases, thus the proteinases activating ENaCs in the collecting duct (24,26). Larionov et al (27) showed that the activation of ENaCs was protease-dependent. Additionally, the above study revealed that the expression of Na+/K+-ATPase in the collecting duct was also increased when the ENaC was activated. Proteinuria is the major clinical symptom of nephrotic syndrome and is characterized by the presence of serine proteases in the urine. Previous studies suggested that proteinuria is a major mechanism of Na+ retention in patients with nephrotic syndrome and this mechanism has been associated with the activation of Na+ channels (28,29). In nephrotic syndrome models, administration of amiloride or triamterene can reduce Na+ retention in patients by inhibiting ENaCs in distal renal and collecting tubules to prevent Na+ reabsorption. Therefore, amiloride or triamterene can also combat the activation of ENaCs by serine proteases leading to the urinary excretion of active serine proteases in nephrotic syndrome (30). Alternatively, treatment with serine protease inhibitors can attenuate the activation of Na+ channels to reduce proteinuria. Passero et al (31) also indicated that proteases can enhance the activity of ENaCs showing this mechanism is in part involved in proteinuria. In addition, aldosterone, a steroid hormone that mediates Na+ reabsorption in the renal distal nephron of the kidneys by upregulating the expression of the apical membrane ENaCs, has also been associated with podocyte injury and mesangial cell proliferation. Interventional experiments demonstrated that the addition of aldosterone antagonists to the standard therapy significantly alleviates proteinuria in patients with chronic kidney disease (32). The aforementioned findings indicate that the mechanism of proteinuria is associated with ENaCs and their inhibition can decrease proteinuria.
Ca2+ ion channels
Ca2+ channels are transmembrane signaling proteins that tightly regulate the process of Ca2+ entering cells to initiate physiological processes such as the initiation of excitation, excitation-contraction coupling and gene transcription (33,34). Ca2+ channels mainly include voltage-gated Ca2+ channels (VGCCs), ligand-gated Ca2+ channels, TRP channels, Ca2+ library-regulated Ca2+ channels and arachidonic acid-regulated Ca2+ channels (35). Given the importance of Ca2+ homeostasis in cellular processes (such as maintaining the biopotential on both sides of the cell membrane and nerve conduction), Ca2+ regulation is very strict and the kidneys, being one of the main excretory organs of the body, control the filtration and reabsorption of Ca2+ to maintain this homeostasis in the body. It has been reported that ~99% of Ca2+ is reabsorbed in the renal tubules of the kidney (36,37). Ca2+ also affects kidney development, kidney cell function and the occurrence of several kidney diseases, including proteinuria (38,39). This section subsequently focuses on VGCCs and TRP channels.
VGCCs. VGCCs are macromolecular protein complexes embedded in the cell membrane and are highly selective hydrophilic channels that is permeable for Ca2+. VGCCs are composed of 4-5 subunits encoded by multiple genes and play a significant role in regulating the transport of Ca2+ in and out of the cell. Currently, at least 10 genes have been identified that encode VGCC α1 subunits (40,41). All different subtypes of VGCC play different roles in cell signaling. VGCCs are divided into the following six subtypes: i) L-type; ii) N-type; iii) P-type; iv) Q-type; v) R-type; and vi) T-type. The main function of L-type VGCC is excitation-contraction coupling and regulation of gene transcription, while N-type, P-type and Q-type VGCCs are all involved in the release of neurotransmitters. Additionally, R-type VGCCs are involved in pacing and repeated discharge, while T-type Ca2+ channels can attenuate the action potential threshold and enhance prominent excitability (42-45). Hansen (46) suggested that VGCCs serve a key role in vascular smooth muscle cells (VSMCs), cardiomyocytes and renal blood vessels (Fig. 2). Additionally, the aforementioned study showed that cell treatment with Ca2+ channel receptor blockers attenuate proteinuria. A previous study investigated the role L-type and T-type Ca2+ channel blockers in 58 patients with hypertension (47). The results demonstrated that blood pressure and proteinuria are both reduced in patients treated with Ca2+ channel blockers. N-type Ca2+ channels are mainly expressed in the nervous system and it has been reported that L/N-type Ca2+ channel blockers reduce proteinuria after blocking renal sympathetic nerves (48). Furthermore, previous studies have revealed that N-type Ca2+ channels are also expressed in kidney endothelial cells and podocytes, and treatment of injured podocytes in these investigations with L/N-type Ca2+ channel blockers alleviated increased protein expression and pressure fiber dissolution (48-50). In addition, compared with L-type Ca2+ channel blockers, L/N-type and L/T-type VGCCs blockers has been shown to significantly restore the expression of podocin and nephrin and attenuate proteinuria and podocyte injury (51-54). This effect could be due to the effects of N-type and T-type VGCCs on intrarenal pressure and renal hemodynamics. Another study showed that the expression levels of P/Q-type VGCCs is similar with those of L-type VGCCs in renal blood vessels and that these channels are involved in regulating renal vasoconstriction (55). The aforementioned results suggest that VGCC blocking can reduce proteinuria.
TRP channels
TRP channels, a class of cationic channel proteins, act as signal converters via altering membrane potential or the intracellular concentration of Ca2+ (56,57). In 1989, Montell and Rubin (58) identified the TRP ion channels. TRP channels can be divided into the following six subfamilies: i) TRPA (ankyrin); ii) TRPC (canonical); iii) TRPM (melastatin); iv) TRPML (mucolipin); v) TRPP (polycystin); and vi) TRPV (vanilloid) (59-61). TRP channels can be activated through several pathways, such as intracellular or extracellular transmitters, chemical stimulation and osmotic pressure. Furthermore, the body can perceive the changes of the external environment through the instantaneous receptor potential channels in the surrounding environment, thus protecting the body (62-67). The current review article focused on the roles of TRPC and TRPV4 on proteinuria.
The members of the TRPC subfamily can act as both Ca2+ pool regulatory channels and receptors to regulate other Ca2+ channels. A total of seven different TRPC members have been identified in mammals that can be subdivided into the following four subgroups based on their protein sequence and function: i) TRPC1; ii) TRPC2; iii) TRPC4/5; and iv) TRPC3/6/7. Among them, TRPC2 is not expressed in humans (68). Previous studies demonstrated that only TRPC3, TRPC5 and TRPC6 were able to promote podocyte Ca2+ entry (69-71). Currently, the role of TRPC family members in several kidney diseases has become increasingly important. Specifically, it has been reported that TRPC5 mediates the activation of ras-related C3 botulinum toxin substrate 1, a member of the Rho GTPase family and synaptic lipoprotein degradation involved in the cytoskeleton hub structure of podocytes (72). Additionally, TRPC6 can affect the movement of podocytes by regulating RhoA (Fig. 3) (73). Another study showed that TRPC6, an important ion channel in podocytes, can interact with other SD proteins, as well as with signal transduction molecules such as vascular endothelial growth factor to regulate the actin cytoskeleton rearrangement of podocytes, thus affecting pathological proteinuria (74). It has been also reported that TRPC6 is upregulated in renal diseases, commonly accompanied by proteinuria, including membranous nephropathy, focal glomerulopathy and minor pathological nephropathy (75-77). Since TRPC6 is considered to be one of the most significant podocyte cleft membrane proteins involved in proteinuria and it can be used as a therapeutic target to improve proteinuria and to delay the development of kidney diseases (78-80). Reiser et al (81) demonstrated that TRPC6 overexpression increased proteinuria in mice. After podocytes were transfected with a circular TRPC6 overexpression plasmid, Ca2+ concentration and the enzymatic activity of RhoA increased in podocytes, resulting in podocyte cytoskeletal remodeling, podocyte contraction, a reduced number of podocytes and disordered F-actin distribution. The aforementioned effects were remediated after the administration of RhoA inhibitors. This indicated that TRPC6 overexpression, which increases intracellular Ca2+ concentration and activates the Ca2+-dependent RhoA signaling pathway, can result in podocyte damage and the onset of proteinuria (82). Proteinuria and podocyte shedding are also inhibited in systemic TRPC5 knockdown animal models. To evaluate the role of TRPC5 in different diseases, Zhou et al (83) showed that mice treated with the TRPC5-specific inhibitor AC1903 demonstrate reduced proteinuria and loss of podocytes. Therefore, targeting TRPC5 can serve as a treatment approach for reducing proteinuria. Another study revealed that podocyte treatment with angiotensin II, which activates the ERK signaling pathway and promotes translocation of NF-kB, a transcription factor involved in TRPC upregulation, increases Ca2+ influx, promotes podocyte apoptosis and enhances proteinuria (84). Alternatively, Wang et al (85) demonstrated in a puromycin-induced podocyte injury model that enhanced NADPH oxidase activity upregulated TRPC6 expression and increased Ca2+ influx, thus promoting proteinuria. The above studies suggest that the normal function and structure of podocytes can be maintained by regulating the abnormal expression of TRPC6 and TRPC5 to reduce proteinuria (86,87).
The TRPV4 receptor is expressed in the cardiovascular system, including endothelial cells, cardiac fibroblasts, VSMCs and perivascular nerves, but also in the kidneys. This receptor can be activated by physical factors such as high temperature and mechanical stimulation as well as by chemical factors such as arachidonic acid (88-92). Gualdani et al (93) showed that fluid flow-induced mechanical force in proximal renal tubules activates TRPV4 and promotes the endocytosis of albumin in proximal renal tubular epithelial cells (Fig. 4), thus promoting albumin retention. Perineuria is also significantly increased in TRPV4-depleted tubular cells in mice when the glomerular filter permeability in the proximal tubules is enhanced. Taken together, the TRPV4-mediated defects in endocytosis may underlie proteinuria and therefore TRPV4 receptors can be considered as promising targets for controlling proteinuria (93).
Cl- ion channels
Cl- channels are expressed in cell membranes and organelles and are of great significance, including stabilization of membrane potential and fluid transport. These channels can be divided into five categories: i) voltage-dependent Cl- channels (ClCs); ii) cystic fiber transmembrane conductance regulators; iii) Ca2+-activated Cl- channels (CaCCs); iv) volume regulatory Cl- channels; and v) ligand-gated Cl- channels (94-98). Among them, voltage-dependent ClCs and CaCCs are involved in the occurrence of proteinuria. In mammals, voltage-dependent ClCs include nine members, with ClC-0, ClC-1, ClC-2, ClC-Ka and ClC-Kb commonly found in the cell membrane and ClC-3, ClC-4, ClC-5 and ClC-7 in organelle membranes (99,100). Among them, ClC-Ka, ClC-Kb and ClC-5 are expressed in the kidneys and serve a key role in the reabsorption of renal tubular Cl- (101,102). ClC-5 is mainly expressed in proximal renal and collecting tubules and regulates cytoplasmic membrane currents (103). ClC-5 serves a significant role in proximal tubular endocytosis and intracellular function (Fig. 5), connotation acidification, receptor regulation, intracellular maturation and enzyme activation (104). It has been reported that the damage caused by urinary protein in renal tubular epithelial cells leads to diminished proton pump expression in the intracellular connotation epitope membrane, thus affecting ClC-5 expression and Cl- transport. During proteinuria reuptake, damage to renal tubular epithelial cells can also be caused, and direct or indirect ClC-5 downregulation can affect protein absorption via the proximal renal tubules to increase proteinuria (104-106). A previous study showed that ClC-5 depletion in a knockdown mouse model reduced phosphorylation compared with wild-type mice, resulting in impaired invagination function and proteinuria (107). CaCCs are widely expressed in non-excitatory cells, such as endothelial cells, epithelial cells and VSMCs and play key roles in several processes. Transmembrane member 16A (TMEM16A) is involved in Ca2+ activation of Cl- channels and is associated with the formation of CaCCs. TMEM16A is prominently expressed in renal tubular proximal epithelial cells, but also in podocytes and other renal tubular segments (108). Previous studies demonstrated that the ability of tubular proximal epithelial cells to reabsorb protein is reduced and excretion was enhanced in TMEM16A-depleted mice, subsequently promoting proteinuria (109).
K+ ion channels
K+ channels specifically allow K+, but not other ions, especially Na+, to pass through the plasma membrane. The molecular structure of K+ channels consists of the T1 tetrameric functional domain of the amino-terminal cytosolic domain, six transmembrane-helical domains, the voltage sensing domain, the pore region and an intracellular carboxylated cytosolic domain (110-112). K+ channels can be divided into K+ channels with only pore-forming areas, voltage-gated K+ channels, inward rectifier K+ channels and ligand-gated K+ channels (113). A novel ATP-sensitive K+ channel was identified on the mitochondrial membrane, which belongs to the inward rectifying K+ channels, where the channel activity is inhibited when intracellular ATP concentration increases (Fig. 6) (114-117). Among the aforementioned channels, voltage-gated K+ channels, also known as voltage-dependent K+ channels, can be further divided into delayed rectifier K+ channels (Kr), type A transient K+ channels (KA) and Ca2+-activated K+ channels (KCa) (118-123).
K+ channels are distributed in the apical and basement membrane of the renal tubules at several segments of the kidney (124). It has been suggested that K+ conductance plays an important role in VSMC and endothelial cell membrane potential in the kidneys. Therefore, changes in the activity of K+ channels may cause changes in hemodynamic resistance, kidney blood flow and glomerular filtration pressure, thus affecting the excretion of substances into the urine (125). A previous study revealed that nicorandil, an activator of the ATP-dependent K+ channel, exerts a protective effect on the renal vasculature. The nicorandil treatment of mice in an acute kidney injury and glomerulonephritis model significantly reduces proteinuria and kidney injury by inhibiting oxidative stress (126). Additionally, Snijder et al (127) used H2S intervention to explore its protective effect on angiotensin-induced hypertensive nephropathy mice. The results demonstrated that H2S activates ATP-sensitive K+ channels to attenuate angiotensin-related podocyte injury and intrarenal pressure, thus alleviating proteinuria and kidney injury. Voltage-gated K+ channels can be expressed in glomeruli as well as in portions of the renal tubules. In a study using an anti-glomerular basement membrane glomerulonephritis mouse model, treatment of mice with K+ channel blockers significantly reduced urinary protein (128). In addition, Huang et al (129) subcutaneously injected streptozotocin-induced diabetic nephropathy mice with a KCa inhibitor to evaluate proteinuria, the expression of renal inflammation-related markers and ECM precipitation. The results showed that KCa inhibitors decrease the expression of inflammation-related markers and attenuate proteinuria by inhibiting TGF-β1 signaling to reduce kidney injury. Piwkowska et al (130) investigated whether BKCa is involved in insulin-mediated and protein kinase type GI (PKGI) protein-dependent glomerular filtration barrier permeability. This study showed that a BKCa blocker is able to attenuate the flow of insulin-induced albumin and PKGI-dependent trans-epithelial albumin through the podocyte monolayer by reducing the permeability of the cell filtration barrier, eventually alleviating the excretion of proteins in the urine. This finding could also provide a novel therapeutic target for reducing proteinuria.
Ion transporters
Transporters are the other types of membrane proteins that mediate the flow of ions through the cell membrane. These proteins are different from ion channels. Pumps, the main active transporters, use energy generated by ATP hydrolysis to transport ions against electrochemical gradients, independent of passive diffusion (131). In addition, pumps are involved in several activities, such as maintaining ion homeostasis by regulating the activity of pumps, and require one or more proteins to maintain, including Na+/K+-ATPases and Na+/H+ exchanger proteins (131,132). Orlov et al (133) showed that proteinuria is associated with abnormalities in the ion transporter Na+/H+ exchange factor and Na+/K+/2Cl- co-transporter in a human model of primary hypertension. Hypertension and proteinuria are the main features of preeclampsia (134). Graves (134) demonstrated that the above effect is partially due to defects in Na+/K+-ATPases or Na+ pumps. ClC-5 is the Cl-/H+ anti-transporter expressed in early proximal tubular endosomes (135). When the function of ClC-5 is impaired in endosomes, not only is the expression of Na+/H+ exchange factors on the apical surface of proximal tubules altered, but also reabsorption of low molecular weight proteins and proximal tubular cell dysfunction are observed, thus leading to albuminuria (135-137). A study on a nephrotic syndrome rat model revealed that amiloride-sensitive ENaCs are activated and the expression levels of Na+ transporters are reduced in proximal renal tubules, which may be due to the compensatory function (138). Furthermore, Gadau et al (139) used an anti-Thy1 vasoproliferative glomerulonephritis rat model to evaluate the association between the changes in Na+ and water homeostasis and those in the renal tubular epithelium with Na+ retention. The results showed that the abundance of salt and water transporters (Na+/H+ exchanger-3, Na+/K+/2Cl- co-transporter and aquaprin-1) in the proximal tubular brush border membrane decreased, thus indicating that ion transporters are a relevant mechanism of channel activation in glomerular diseases. These findings suggest that there is an association between the above mechanism and the occurrence and development of proteinuria. In addition, de Seigneux et al (140) investigated the association between proteinuria and phosphoremia in a nephrotic proteinuria mouse model. The results showed that expression of Na+/Na+ phosphate apical symporter is abnormal in mice with proteinuria, while the albuminuria-induced alterations on phosphate tubular handling are not associated with the glomerular filtration rate. Another study by Shimizu et al (141) exploring the effects of N-acetylcysteine on kidney function and Na+ and water transporters in mice, showed that Na+/K+/2Cl- co-transporter 2 and aquaporin 2 are both upregulated and proteinuria is alleviated in mice in that received the treatment. The above studies support an association between proteinuria and ion transporters, thus indicating that ion transporters could also be considered as therapeutic targets for reducing proteinuria in patients.